The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2025.116162 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Paul Lorigan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Sciences, University of Manchester and Christie Hospital NHS Foundation Trust, Manchester, United Kingdom. Electronic address: pau…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Cancer Vaccines, Ipilimumab, Melanoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer Sciences, University of Manchester and Christie Hospital NHS Foundation Trust, Manchester, United Kingdom. Electronic address: paul.lorigan@nhs.net.
- University of Colorado Comprehensive Cancer Center, Aurora, CO, United States.
- Oslo University Hospital, Oslo, Norway.
- AZ Sint-Augustinus (Belgium), Antwerpen, Belgium.
- Sylvester Comprehensive Cancer Center, Miami, FL, United States.
- Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, United States.
Zitieren
APA
Lorigan, P., Medina, T. M., Nyakas, M., Rutten, A., Feun, L. G., Cowey, C. L., Payne, M., Hussain, I., Kuzel, T., O'Day, S., Sheri, A., Friedlander, P. A., Kumar, S., Bergersen, V. S., Foss, Ø., Ellingsen, E. B., Bjørheim, J., & Bechter, O. E. (2026). The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.116162
Vancouver
Lorigan P, Medina TM, Nyakas M, Rutten A, Feun LG, Cowey CL, et al. The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2025.116162
BibTeX
@article{Lorigan2026,
author = {Lorigan, Paul and Medina, Theresa Michelle and Nyakas, Marta and Rutten, Annemie and Feun, Lynn G and Cowey, Charles Lance and Payne, Miranda and Hussain, Israr and Kuzel, Timothy and O'Day, Steven and Sheri, Amna and Friedlander, Philip Adam and Kumar, Satish and Bergersen, Vanja Sue and Foss, Øivind and Ellingsen, Espen Basmo and Bjørheim, Jens and Bechter, Oliver Edgar},
title = {The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2025.116162}
}
EUVIMED